Lanzavecchia’s laboratory investigates the mechanisms of antibody-mediated resistance to infectious diseases. They use high-throughput cellular screens to isolate potent and broadly neutralizing antibodies, which can be developed for prophylaxis and treatment of infectious diseases and used as tools for vaccine design. They also address fundamental aspects of the antibody response, such as the role of somatic mutations in affinity maturation and the relationship between infection and autoimmunity. Recently, they discovered in malaria-immune individuals a new mechanism of antibody diversification that involves insertions of templated DNA sequences into immunoglobulin genes.
Projects
Group leaders: Antonio Lanzavecchia
Status: In progress
A new mechanism of antibody diversification through templated insertions
Group leaders: Antonio Lanzavecchia
Status: In progress
Exploiting new formats of bispecific antibodies
Group leaders: Antonio Lanzavecchia
Status: In progress
Harnessing monoclonal antibodies against M. tuberculosis
Group leaders: Antonio Lanzavecchia
Status: In progress
Memory B cells and plasma cells
Group leaders: Antonio Lanzavecchia
Status: In progress
Molecular mechanisms leading to autoantibodies
Group leaders: Antonio Lanzavecchia
Status: In progress
Pathogenic mechanisms in light chain amyloidosis.
Group leaders: Antonio Lanzavecchia
Status: In progress
Site-specific quantitative serology.
Group leaders: Antonio Lanzavecchia
Status: In progress
The human antibody response to P. falciparum.
Group leaders: Antonio Lanzavecchia
Status: In progress
Vaccinal effect of antibodies.
Via Vincenzo Vela 6
6500 Bellinzona, Switzerland
Tel. +41 91 820 0300
Fax +41 91 820 0302
Facebook / Twitter